Weight-loss Generic Drugs
Context:
The Indian market for weight-loss and diabetes medications is undergoing a massive transformation following the expiry of the patent on Danish drugmaker Novo Nordisk's blockbuster drug, semaglutide.
Sold previously under the innovator brands like Ozempic and Wegovy, the patent expiry allows a flood of generic versions to hit the shelves
Market Impact and Affordability:
The entry of generic manufacturers is expected to bring price discounts as deep as 70-90%.
The overall cost for patients is projected to drop by at least a third to a fifth of the existing prices, significantly increasing accessibility to the medication.
Domestic drugmakers like Natco Pharmaceuticals and Eris Lifesciences are entering the market with generic multi-dose vials starting at just ₹1,290 per month for the lowest dose.
Other major pharmaceutical companies, including Zydus, Lupin, and Torrent, are also launching their own branded versions of semaglutide.
Prior to this, India's GLP-1 (glucagon-like peptide-1) drugs market was valued at around ₹1,500 crore, heavily dominated by Eli Lilly's Monjaro and Novo Nordisk's products.
Due to the steep price cuts and improved affordability, analysts expect a two-fold jump in the sale of GLP-1 units over the next three months.
Shifting Paradigms in Obesity Treatment:
Chronic Disease Classification:
These drugs have changed how obesity is treated.
The World Health Organisation (WHO) now formally considers obesity a "lifelong, chronic disease that requires holistic care," recommending these new GLP-1 therapies for long-term treatment in adults.
Redefining Obesity:
Moving away from relying solely on a simple BMI measurement, a recent Lancet Commission differentiated between "pre-clinical obesity" (a physical attribute) and "clinical obesity".
Clinical Obesity:
This is defined as a chronic illness that results in alterations in organ functions and can lead to life-threatening complications, regardless of other underlying conditions a person might have.
Consequently, governments are urged to create health systems geared towards life-long screening, diagnosis, and treatment of obesity.